MAVS

Across TCGA pan-cancer cohorts, MAVS mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MAVS data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAVS mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAVS expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where MAVS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.560	0.195	.003	18	view →
LSCC	OS	Median	All	0.669	0.884	.005	9	view →
LUAD	DFS	Median	II,III,IV	0.311	0.686	.004	9	view →
CCRCC	DFS	Quartile	III,IV	0.140	0.830	.038	6	view →
HNSC	DFS	Median	All	0.717	0.845	.025	4	view →
GBM	DFS	Quartile	All	0.870	0.583	.016	3	view →
UCEC	DFS	Tertile	All	0.923	1.000	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MAVS–PDAC (DFS)

Open the PDAC breakdown →